Skip to content
Font Size

Genes With Potential Clinical Relevance in Prostate Cancer Risk

    Table 3. Case-Control Studies in Ashkenazi Jewish Populations ofBRCA1andBRCA2and Prostate Cancer Risk

    StudyPopulationControlsMutation Frequency (BRCA1)Mutation Frequency (BRCA2)Prostate Cancer Risk (BRCA1)Prostate Cancer Risk (BRCA2)Comments
    AJ = Ashkenazi Jewish; CI = confidence interval; MECC = Molecular Epidemiology of Colorectal Cancer; OR = odds ratio; WAS = Washington Ashkenazi Study.
    Guisti et al., 2003[13]979 consecutive AJ men from Israel diagnosed with prostate cancer between 1994 and 1995Prevalence of founder mutations compared with age-matched controls >50 years with no history of prostate cancer from the WAS study and the MECC study from IsraelCases: 16 (1.7%)Cases: 14 (1.5%)185delAG: OR, 2.52 (95% CI, 1.05–6.04)OR, 2.02 (95% CI, 0.16–5.72)There was no evidence of unique or specific histopathology findings within the mutation-associated prostate cancers.
    Controls: 11 (0.81%)Controls: 10 (0.74%)5282insC: OR, 0.22 (95% CI, 0.16–5.72)
    Kirchoff et al., 2004[14]251 unselected AJ men treated for prostate cancer between 2000 and 20021,472 AJ men with no history of cancerCases: 5 (2.0%)Cases: 8 (3.2%)OR, 2.20 (95% CI, 0.72–6.70)OR, 4.78 (95% CI, 1.87–12.25) 
    Controls: 12 (0.8%)Controls: 16 (1.1%)
    Agalliu et al., 2009[15]979 AJ men diagnosed with prostate cancer between 1978 and 2005 (mean and median year of diagnosis: 1996)1,251 AJ men with no history of cancerCases: 12 (1.2%)Cases: 18 (1.9%)OR, 1.39 (95% CI, 0.60–3.22)OR, 1.92 (95% CI, 0.91–4.07)Gleason score 7–10 prostate cancer was more common inBRCA1mutation carriers (OR, 2.23; 95% CI, 0.84–5.86) andBRCA2mutation carriers (OR, 3.18; 95% CI, 1.62–6.24) than in controls.
    Controls: 11 (0.9%)Controls: 12 (1.0%)
    Gallagher et al., 2010[16]832 AJ men diagnosed with localized prostate cancer between 1988 and 2007454 AJ men with no history of cancerNoncarriers: 806 (96.9%)Noncarriers: 447 (98.5%)OR, 0.38 (95% CI, 0.05–2.75)OR, 3.18 (95% CI, 1.52–6.66)TheBRCA15382insC founder mutation was not tested in this series, so it is likely that some carriers of this mutation were not identified. Consequently,BRCA1-related risk may be underestimated. Gleason score 7–10 prostate cancer was more common inBRCA2mutation carriers (85%) than in noncarriers (57%);P = .0002.BRCA1/2mutation carriers had significantly greater risk of recurrence and prostate cancer–specific death than did noncarriers.
    Cases: 6 (0.7%)Cases: 20 (2.4%)
    Controls: 4 (0.9%)Controls: 3 (0.7%)
    1|2|3|4|5|6|7|8|9

    Today on WebMD

    man with doctor
    Symptoms, risks, treatments
    man coughing
    Men shouldn’t ignore
     
    prostate cancer cells
    What does this diagnosis mean?
    doctor and male patient
    Is it worth it?
     
    cancer fighting foods
    SLIDESHOW
    15 Cancer Symptoms Men Ignore
    FEATURE
     
    Prostate Enlarged
    VIDEO
    Picture Of The Prostate
    ANATOMY
     
    Prostate Cancer Quiz
    QUIZ
    screening tests for men
    SLIDESHOW
     
    Prostate Cancer Symptoms
    VIDEO
    Vitamin D
    SLIDESHOW